Molecular MR Imaging of Prostate Cancer by Specified Iron Oxide Nanoparticles With PSMA‐11 Peptides: A Preclinical Study

Abstract

BackgroundProstate‐specific membrane antigen (PSMA) can provide a prostate cancer (PCa) detection approach in positron emission tomography (PET) using Food and Drug Administration (FDA)‐approved PSMA‐11 peptide. There are some studies evaluated magnetic‐nanoprobes for PSMA detection by MRI, using non‐FDA‐approved ligands including antibodies or peptides, which are not as specific as PSMA‐11.PurposeTo assess targeted iron oxide nanoparticles (IONPs) by PSMA‐11 peptides as a potential specific nano‐molecular probes to investigate a PSMA+ PCa‐xenograft model by MRI.Study TypeProspective.Animal ModelTwenty male C57BL6 nude mice induced subcutaneously PSMA+ LNCaP cell line tumor.Field Strength/Sequence1.5 T, T2‐W Fast Spin echo and T2*‐W Gradient echo.AssessmentCoated IONPs with Carboxymethylated‐dextran (DNPs) and with bovine serum albumin (BNPs), as well as, targeted DNPs with PSMA‐11‐HYNIC peptide (TDNPs) and targeted BNPs with PSMA‐11‐HBED peptide (TBNPs) were injected intravenously with dose 2.8 mg Fe/kg. Coronal T2‐W and the T2*‐W images were obtained before and 4 hours and 6 hours post‐injection. Signal intensity (SI) and relative signal enhancement (RSE) were computed in two‐ and three‐dimensional analyses. Histological analysis of tumors was evaluated, and the Fe distribution within the body based on atomic absorption spectroscopy was calculated.Statistical TestsOne‐way ANOVA followed by Tukey's multiple comparison test, Paired‐samples T‐test, P < 0.05 was considered significant.ResultsA reduction in T2‐W SI was achieved as 22 ± 7%, 59 ± 3%, 65 ± 5%, and 78 ± 3% respectively for BNPs, TBNPs, DNPs, and TDNPs 6 hours post‐injection. The most difference between targeted and non‐targeted groups was observed at 6 hours for PSMA‐11‐HBED, and at 4 hours for PSMA‐11‐HYNIC. RSE indicated 88.6 ± 3.1% and 80.7 ± 3.2% enhanced contrast between tumor and muscle region for TBNPs and TDNPs on T2*‐W images.ConclusionsBoth TBNPs and TDNPs are promising novel nano‐molecular probes for PSMA+ PCa tumor detection. The injection dose of non‐targeted IONPs can be reduced by using targeted nanoprobes three times for BNPs and two times for DNPs.Evidence Level1Technical EfficacyStage 1

Surface ligand-regulated renal clearance of MRI/SPECT dual-modality nanoprobes for tumor imaging

“…The MRI contrast enhancement effects of these nanoparticles were then carefully evaluated. MRI is one of the most widely used imaging techniques renowned for its ability to provide detailed anatomical information with superb spatial resolution and unlimited penetration depth, without involving ionizing radiation [ 46 – 48 ]. To assess the performance of these nanoparticles as MRI contrast agents, in vitro MR imaging experiments were carried out on a 3.0 T MR scanner.…”